Journal
DRUGS OF THE FUTURE
Volume 34, Issue 5, Pages 352-357Publisher
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dof.2009.034.05.1370787
Keywords
CNTO-148; Simponi (TM)
Categories
Ask authors/readers for more resources
Golimumab (CNTO-148, Simponi (TM)) is a new human monoclonal-antibody under development by Centocor that targets and neutralizes the proinflammatory cytokine TNF-alpha This review summarizes in vitro and in vivo publications and highlights the clinical efficacy and safety data presented to dote (i.e., the CO-REVEAL, GO-RAISE, CO-FORWARD and GO-AFTER trials). These clinical findings have led to the recent approval of golimumab in Canada and the U.S. as a once-monthly S.C. treatment for adults with moderate to severe active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. A request for European approval has recently been submitted. Clinical trials ore also under way in ulcerative colitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available